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INTRODUCTION
Camurati-Engelmann disease (CED) (Mendelian Inheri-
tance in Man 131300), also known as progressive diaphyseal
dysplasia (PDD), is a rare disease that occurs in both genders
with equal frequency and is inherited in an autosomal domi-
nant pattern with variable penetrance and wide expressivity
(1-3). Considerable variations in signs, symptoms, and sever-
ity between afflicted individuals exist within the same fami-
ly (2, 3). The main clinical symptoms are pain in the legs,
waddling gait, muscular weakness, and easy fatigability (1-
3). Other associated symptoms include reduced muscle mass,
exophthalmus, facial paralysis, hearing difficulty, and loss of
vision. There are no specific laboratory findings or ultrastruc-
tural muscular abnormalities that are known but radiograph-
ic abnormalities are remarkably constant and distinctive. CED
is a disease of endosteal and periosteal thickening and expan-
sion of the diaphyses of the long bones. This results in corti-
cal thickening, narrowing of the medullary cavity and a scle-
rotic and expanded diaphyseal segment (4, 5). Recently, the
locus for CED was assigned to chromosomal region 19q13.1
and mutations have been found in the transforming growth
factor-β 1 (TGFB1) gene (1, 6). We report the first Korean
CED family with 2 affected individuals confirmed by muta-
tion analysis.
CASE REPORT
A 19-yr-old Korean male with a history of abnormal gait
since the age of 2 was referred for molecular genetic testing.
His symptoms included wide base waddling gait, proximal
muscle weakness, pain in the extremities, and easy fatigabili-
ty. He had no history of trauma, infection, or systemic illness.
Physical examination showed no abnormalities in his reflexes
and he was able to walk independently. The 53-yr-old moth-
er of the proband had only mild limb pain with an onset after
the fourth decade that subsided with steroid treatment but
she had never previously received a conclusive diagnosis des-
pite multiple visits to several hospitals. Other family mem-
bers, including the proband’s father and 2 younger brothers,
did not show any symptoms of muscle weakness (Fig. 1).
Radiographs of the proband showed cortical, periosteal,
and endosteal bony thickening with narrowing of the med-
ullary spaces confined to the diaphyses of the femur, tibia,
and fibula (Fig. 2A). The epiphyses and metaphyses of the
long bones are relatively spared. In the upper extremity, the
ulna is rather severely affected than the radius (Fig. 2B, C).
The humerus showed only mild cortical thickening. Some
curvature changes were seen in both tibias with genu valgus
changes of both knees. Scoliosis of the thoracic and lumbar
spines with mild kyphosis of the thoracic spines was also
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The First Korean Case of Camurati-Engelmann Disease (Progressive
Diaphyseal Dysplasia) Confirmed by TGFB1 Gene Mutation Analysis
Camurati-Engelmann disease (CED) is an autosomal dominant progressive diaphy-
seal dysplasia caused by mutations in the transforming growth factor-β 1 (TGFB1)
gene. We report the first Korean family with an affected mother and son who were
diagnosed with CED. The proband is a 19-yr-old male with a history of abnormal
gait since the age of 2. He also suffered from proximal muscle weakness, pain in
the extremities, and easy fatigability. Skeletal radiographs of the long bones revealed
cortical, periosteal, and endosteal thickenings, predominantly affecting the diaphy-
ses of the upper and lower extremities. No other bony abnormalities were noted in
the skull and spine and no remarkable findings were seen on laboratory tests. The
patient’s mother had a long-standing history of mild limb pain. Under the impression
of CED on radiographic studies, we performed mutation analysis. A heterozygous
G to A transition at cDNA position +653 in exon 4 of the TGFB1 gene (R218H) was
detected in the patient and his mother.
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Accepted : 19 April 2008observed. No other gross bony abnormality was seen in the
skull (Fig. 2D). The chest radiography was unremarkable.
Skeletal radiograph of the lower extremities in the proband’s
mother showed similar diaphyseal thickening and sclerosis
of the femur and tibia with undermodeling of distal femur
and proximal tibia (Fig. 3).
Laboratory findings in the patient indicated normal val-
ues for serum levels of electrolytes, calcium, and phosphate.
Serum alkaline phosphatase was mildly elevated (139 IU/L;
reference range, 42-117 IU/L) and peripheral blood analysis
showed slight increase in ESR level (24 mm/hr; reference
range, 0-15 mm/hr). 
Muscle biopsy was performed at the patient’s right vastus
lateralis, which did not show any pathologic findings. Degen-
erating or regenerating fibers were not seen and immuno-
histochemical staining for dystrophin was normal along the
membranes of the muscle fibers.
Genomic DNA samples after written informed consent
were obtained from the patient and his mother. Exon 4 of
the TGFB1 gene was targeted for molecular testing since this
region is a mutation hot spot that includes approximately
80% of all mutations reported so far (1). Primers (forward:
5′ -GGTTTGCTCCTTCCTTCCTC-3′ , reverse: 5′ -GCA-
GATGGGAACACACACAC-3′ ) were designed to amplify
exon 4 of the TGFB1 gene and direct sequencing was carried
out on an ABI 310 automated sequencer (Applied Biosys-
tems, Foster City, CA, U.S.A.). Identical mutations of het-
erozygous G to A transition at cDNA position +653 (Fig. 4)
were detected in both the proband and mother, which is pre-
dicted to result in an arginine to histidine substitution at
amino acid 218 (R218H) near the carboxy terminus of the
latency-associated peptide (LAP). This mutation had been
previously reported in CED patients (7, 8).
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Fig. 1. Family pedigree of this study. The arrow indicates the pro-
band.
M/55
M/19 M/17 M/13
F/53
Fig. 2. Standing AP radiograph of the lower limbs (A), scannograms
of the right (B) and left (C) upper limb, and right lateral view of the
skull (D) of the proband. Cortical and periosteal thickenings con-
fined to the diaphyses are seen in all long bones. Gross bony ab-
normalities were not seen in the skull.
A
B C
D
Fig. 3. AP scannogram of the lower
extremity of the proband's mother. Co-
rtical and periosteal thickening with
sclerosis confined to the diaphyses is
also noted. Mild undermodeling is se-
en in the distal femurs and proximal
tibias.
Fig. 4. Direct sequencing of exon 4 of the TGFB1 gene of the pro-
band shows a heterozygous transition at cDNA position +653
(R218H). This mutation in the TGFB1 gene was detected in both
the proband and his mother.
Forward
GG G C TTT C N CC TTA G C G C
G C G C T AA GG N G AAA G CCC
ReverseDISCUSSION
Forty-five CED families have been described worldwide
to date from Europe, Asia, Africa, North America, and Aus-
tralia (1). CED patients usually have a positive family history
showing an autosomal dominant mode of inheritance. Vari-
able penetrance has given rise to a broad range of descriptions:
lethal disease, disabled patients, and even patients whose ra-
diographic abnormalities almost were incidental findings (2,
3). The age of presentation ranges from the first to the eighth
decade depending on the clinical subtype (9). The extreme
variability in phenotypical expression, both between fami-
lies sharing the same mutation and among members of the
same family, makes it difficult to detect possible genotype-
phenotype correlations. Even in the present case, the patient
and his mother showed different phenotypical expression
despite having identical mutations in a region known to be
associated with CED. Irrespective of the nature of the muta-
tion, the age of onset and rate of disease progression appear
highly unpredictable.
Prior to the definition of the molecular defect, Saraiva (10)
proposed that CED might show anticipation because younger
members were often more severely affected than their par-
ents. Another report by Saraiva (11) supports the occurrence
of anticipation in CED and widens the disease spectrum of
this concept to bone dysplasias. The patient had a waddling
gait since the age of 2 and was diagnosed in his second decade
of life whereas the mother had only mild symptoms of late
onset and was diagnosed during diagnostic workup of her
son; therefore, genetic counseling may be recommended in
successive generations in this family.
CED can be associated with neurologic symptoms, includ-
ing headache, hearing loss, vertigo, and tinnitus, which have
been previously noted in a study of a family through 4 gen-
erations with extensive skull involvement (2). The most co-
mmon deficits are hearing loss, vision problems, and facial
paralysis. In our study, the proband complained of recently
developed facial muscle twitching. Despite having no abnor-
malities in radiologic findings of the skull, close monitoring
for progression of symptoms should be considered in the pa-
tient.
The TGFB1 gene, which influences osteoblast and osteo-
clast function, is thought to act as a coupling factor between
bone deposition and resorption (12). In addition, it has been
reported that CED is caused by mutations in the gene encod-
ing for TGFB1 (7, 8, 12, 13). With the presence of an acti-
vating mutation in the TGFB1 gene, the inhibiting effect of
TGFB1 on osteoclast differentiation and activation and its
stimulatory effect on osteoblast chemotaxis, proliferation, and
differentiation will be enhanced (12). The missense mutation
seen in both the patient and his mother (R218H) was locat-
ed in a mutation hotspot, which represents 60% of the muta-
tions (1). The majority of mutations detected in CED are mi-
ssense mutations located in exon 4, coding for the region in
the latency associated peptide surrounding the residues res-
ponsible for homodimerisation (Cys 223 and Cys 225), mak-
ing up 82.2% of all mutations reported so far (1). 
The incidence of CED tends to be underestimated since
patients illustrate marked phenotypic variability. This patient
had initially been tested for muscular dystrophy and the dis-
ease was ruled out with negative muscle biopsy findings. Like
this case, many children who present symptoms of waddling
gait, decreased muscle bulk and/or tone, fatigue, and weak-
ness are often incorrectly diagnosed with muscular dystro-
phy or delayed diagnosis (2).
Diagnosis of CED is based on a combination of a thorough
family history, physical examination, and radiologic studies
with the utilization of molecular genetic testing for confir-
mation. Since TGFB1 is the only gene known to be associ-
ated with CED and the hot spot for mutations is known, di-
agnosis can be easily confirmed by mutation analysis. More-
over, with the identification of the first case of CED in a Ko-
rean family in addition to previously accumulated data of
Asian cases, CED can presumably affect all races. Therefore,
we need to keep a high index of suspicion in Korean patients
with symptoms suggestive of CED.
In conclusion, this report describes the first confirmed Ko-
rean family with CED. Both the proband and his mother had
symptoms and radiologic findings suggestive of CED and
was confirmed with mutation analysis of the TGFB1 gene.
The patient should be monitored closely for progression of
the disease, including skull involvement.
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